

CONTENTS

| | |
|---|-----------|
| NOTE TO THE READER | 1 |
| LIST OF PARTICIPANTS | 3 |
| PREAMBLE | |
| Background | 7 |
| Objective and Scope | 7 |
| Selection of Topics for Monographs..... | 8 |
| Data for Monographs | 9 |
| The Working Group | 9 |
| Working Procedures..... | 9 |
| Exposure Data | 10 |
| Studies of Cancer in Humans..... | 12 |
| Studies of Cancer in Experimental Animals..... | 15 |
| Other Data Relevant to an Evaluation of Carcinogenicity and Its Mechanisms..... | 18 |
| Summary of Data Reported | 19 |
| Evaluation | 21 |
| References..... | 25 |
| THE MONOGRAPHS | |
| Human immunodeficiency viruses..... | 31 |
| 1. Exposure data | 31 |
| 1.1 Structure, taxonomy and biology..... | 31 |
| 1.1.1 Structure..... | 31 |
| 1.1.2 Taxonomy..... | 32 |
| 1.1.3 Phylogeny | 33 |
| (a) Phylogenetic relationship of HIV-1 and HIV-2 to other retroviruses..... | 33 |
| (b) Relationship of HIV-1 and HIV-2 isolates to one another | 36 |
| (i) Genotypes..... | 36 |
| (ii) Antigenic diversity | 37 |
| 1.1.4 Host range..... | 37 |
| 1.1.5 Cell tropism | 37 |
| 1.1.6 Target tissues | 38 |
| (a) Lymphoid tissue..... | 38 |
| (b) Central nervous system..... | 38 |
| (c) Gastrointestinal tract | 38 |

| | | |
|-------|--|----|
| 1.1.7 | The HIV-1 and HIV-2 genome and gene products..... | 38 |
| | (i) Structural proteins (Gag, Pol, Env)..... | 39 |
| | (ii) Regulatory proteins (Tat, Rev)..... | 39 |
| | (iii) Accessory proteins (Nef, Vif, Vpr, Vpu)..... | 40 |
| 1.1.8 | Replication..... | 41 |
| 1.2 | Methods of detection..... | 41 |
| 1.2.1 | Antibody tests..... | 41 |
| | (a) ELISA..... | 42 |
| | (b) Western blot analysis..... | 43 |
| | (c) Indeterminate HIV antibody results..... | 43 |
| | (d) Undetectable HIV antibody..... | 43 |
| | (e) Diagnosis of HIV infection in infants..... | 43 |
| | (f) Detection of antibodies in saliva..... | 44 |
| 1.2.2 | Direct detection of HIV..... | 44 |
| | (a) Viral culture..... | 44 |
| | (b) p24 Antigen..... | 44 |
| | (c) Detection of viral genomes..... | 45 |
| | (d) HIV quantification..... | 45 |
| 1.3 | Epidemiology of HIV infection..... | 46 |
| 1.3.1 | HIV transmission..... | 46 |
| | (a) Sexual contact..... | 46 |
| | (b) Blood contact..... | 47 |
| | (c) Mother-to-child transmission..... | 48 |
| | (d) Other modes of transmission..... | 48 |
| 1.3.2 | Geographical distribution..... | 48 |
| | (a) Global estimates and projections..... | 49 |
| | (b) United States and Canada..... | 51 |
| | (c) Caribbean..... | 51 |
| | (d) Latin America..... | 52 |
| | (e) Sub-Saharan Africa..... | 52 |
| | (f) Europe..... | 52 |
| | (g) Asia..... | 52 |
| | (h) Oceania..... | 54 |
| | (i) Middle East..... | 54 |
| 1.4 | Clinical description of non-neoplastic disorders..... | 54 |
| 1.4.1 | Seroconversion syndrome..... | 54 |
| 1.4.2 | Immunological decline..... | 55 |
| 1.4.3 | Non-AIDS-defining manifestations of HIV infection..... | 57 |
| | (a) Classification of HIV disease..... | 57 |
| | (b) Non-AIDS illness..... | 58 |
| | (c) Time to AIDS..... | 59 |
| 1.4.4 | AIDS manifestations..... | 59 |
| 1.4.5 | Long-term non-progressors..... | 60 |
| 1.4.6 | Human immunodeficiency virus type 2 (HIV-2)..... | 61 |

| | | |
|-------|--|----|
| 1.5 | Control and prevention | 61 |
| 1.5.1 | Behavioural prevention | 61 |
| 1.5.2 | Screening | 62 |
| 1.5.3 | Treatment | 63 |
| 1.5.4 | Prospects for vaccines | 64 |
| 1.5.5 | Other approaches | 64 |
| 2. | Studies of cancer in humans | 64 |
| 2.1 | Kaposi's sarcoma | 65 |
| 2.1.1 | Pathology and clinical disease | 65 |
| | (a) Clinical disease in HIV-seronegative individuals | 65 |
| | (b) Clinical disease in HIV-seropositive individuals | 65 |
| 2.1.2 | Descriptive epidemiology of Kaposi's sarcoma | 66 |
| | (a) Demographic variations: age and sex | 66 |
| | (b) Geographical variations | 66 |
| | (c) Temporal changes | 68 |
| 2.1.3 | Descriptive epidemiological studies | 68 |
| | (a) Studies in men in relation to marital status | 68 |
| | (b) Linkage studies between AIDS and cancer registries | 70 |
| 2.1.4 | Analytical studies | 70 |
| | (a) Cohort studies | 70 |
| | (b) Case-control studies | 71 |
| | (c) Analytical studies of the relationship between degree of immunosuppression and Kaposi's sarcoma among HIV infected persons | 71 |
| 2.1.5 | Factors influencing the occurrence of Kaposi's sarcoma in HIV infected persons | 72 |
| | (a) Behavioural cofactors | 72 |
| | (i) Descriptive studies | 72 |
| | (ii) Analytical studies | 78 |
| | (b) Infectious cofactors | 79 |
| | (i) Human herpesvirus 8 | 79 |
| | (ii) Cytomegalovirus | 85 |
| | (iii) Other infectious agents | 86 |
| | (c) Genetic susceptibility | 86 |
| | (d) Miscellaneous factors | 87 |
| 2.1.6 | Human immunodeficiency virus type 2 | 88 |
| 2.2 | Non-Hodgkin's lymphoma | 88 |
| 2.2.1 | Description of the clinical disease and pathology | 88 |
| | (a) Classification of AIDS-related lymphomas | 89 |
| | (i) Systemic non-Hodgkin's lymphomas | 89 |
| | (ii) Body cavity-based lymphoma | 90 |
| | (iii) Primary lymphoma of the brain | 90 |
| | (iv) Multicentric Castleman's disease | 91 |
| | (b) Phenotypic and genotypic features | 91 |

| | | |
|-------|--|-----|
| 2.2.2 | Descriptive epidemiology of non-Hodgkin's lymphoma | 91 |
| | (a) Cancer registry data | 92 |
| | (b) Cohort data | 93 |
| 2.2.3 | Role of immunosuppression | 94 |
| 2.2.4 | Co-factors | 95 |
| | (a) Demographic | 95 |
| | (b) Geographic | 95 |
| | (c) Behavioural | 95 |
| | (d) Infections | 99 |
| | (i) Epstein-Barr virus | 99 |
| | (ii) HHV-8 | 102 |
| | (iii) HHV-6 | 102 |
| | (e) Zidovudine and other therapy | 103 |
| 2.2.5 | HIV-2 and non-Hodgkin's lymphoma | 103 |
| 2.3 | Cervical, anal and other cancers | 103 |
| 2.3.1 | Cervical intraepithelial neoplasia and invasive cancer | 104 |
| | (a) Precancerous lesions | 104 |
| | (i) Association with HIV | 104 |
| | (ii) Association with HIV and HPV | 108 |
| | (iii) HIV, HPV and CD4 ⁺ T-cell counts | 109 |
| | (iv) Progression of disease and treatment of CIN lesions | 111 |
| | (b) Invasive cervical cancer | 111 |
| | (i) Case series | 111 |
| | (ii) Prognosis | 112 |
| | (iii) Descriptive epidemiology | 112 |
| | (iv) Case-control studies | 113 |
| 2.3.2 | Anorectal intraepithelial neoplasia and invasive cancer | 114 |
| | (a) Precancerous lesions | 114 |
| | (i) Association with HIV | 114 |
| | (ii) Association with HIV and HPV | 114 |
| | (iii) HIV, HPV and CD4 ⁺ T-cell count | 117 |
| | (iv) Progression of disease | 119 |
| | (b) Invasive anal cancer | 120 |
| | (i) Case reports and series | 120 |
| | (ii) Prognosis | 120 |
| | (iii) Descriptive epidemiology | 120 |
| 2.3.3 | Hodgkin's disease | 121 |
| | (a) Distribution of histological types | 122 |
| | (i) Hodgkin's disease in HIV-uninfected persons | 122 |
| | (ii) Hodgkin's disease in HIV-infected persons | 122 |
| | (iii) Prognosis | 124 |
| | (b) Descriptive epidemiology | 124 |
| | (c) Cohort studies | 125 |
| | (d) Cofactors | 126 |

| | | |
|-------|---|-----|
| 2.3.4 | Testicular cancer..... | 126 |
| | (a) Case reports and series..... | 126 |
| | (b) Descriptive and cohort studies..... | 127 |
| 2.3.5 | Non-melanoma cancers of the skin..... | 128 |
| | (a) Case reports and series..... | 128 |
| | (b) Descriptive and cohort studies..... | 128 |
| 2.3.6 | Conjunctival tumours..... | 129 |
| | (a) Case reports..... | 129 |
| | (b) Descriptive study..... | 130 |
| | (c) Case-control studies..... | 130 |
| 2.3.7 | Leiomyosarcoma..... | 130 |
| | (a) Case reports and series..... | 130 |
| | (b) Descriptive studies..... | 131 |
| | (c) Cofactors..... | 131 |
| 2.3.8 | Other cancers..... | 131 |
| 3. | Studies of cancer in animals..... | 133 |
| 3.1 | HIV-1 and HIV-2..... | 133 |
| 3.2 | Lymphomas in non-human primates..... | 134 |
| 3.2.1 | Occurrence of lymphomas in nonhuman primates infected with simian immunodeficiency virus..... | 134 |
| 3.2.2 | Pathological and molecular features of lymphoma..... | 135 |
| 3.2.3 | Other neoplastic conditions..... | 135 |
| 3.2.4 | Cofactors in SIV oncogenesis..... | 135 |
| 3.3 | Feline immunodeficiency virus infection in cats..... | 136 |
| 3.3.1 | Occurrence of lymphosarcomas in FIV infection..... | 137 |
| 3.3.2 | Pathological and molecular features of lymphosarcoma..... | 138 |
| 4. | Other data relevant to an evaluation of carcinogenesis and its mechanisms..... | 138 |
| 4.1 | Immunity and cancer..... | 138 |
| 4.1.1 | Types of cancer seen in non-HIV-associated human immunodeficiency..... | 139 |
| 4.1.2 | Time of onset of cancers in non-HIV-associated immunodeficiency..... | 146 |
| 4.1.3 | Similarities and differences between AIDS and transplantation-associated tumours..... | 148 |
| | (a) In immunity..... | 148 |
| | (b) In cancer types..... | 149 |
| | (c) In onset..... | 149 |
| 4.1.4 | Occurrence of other viruses in malignancies associated with non-HIV immunosuppression..... | 150 |
| 4.1.5 | Mechanisms by which immune dysfunction may contribute to the genesis of cancer..... | 150 |
| | (a) Activation of oncogenic viruses with immunosuppression..... | 150 |
| | (b) Stimulation and hyperreactivity of remaining cells in immunosuppressed persons..... | 150 |

| | | |
|-------|--|-----|
| 4.2 | Kaposi's sarcomas | 151 |
| 4.2.1 | Cell biology of Kaposi's sarcoma lesions | 151 |
| | (a) Origins of Kaposi's sarcoma spindle cells | 151 |
| | (b) Vascular lesions induced by Kaposi's sarcoma cell cultures in nude mice | 152 |
| | (c) Growth factors involved in the proliferation of spindle cells .. | 153 |
| | (i) Fibroblast growth factors | 153 |
| | (ii) Platelet-derived growth factor | 154 |
| | (d) Clonality of Kaposi's sarcoma and chromosomal abnormalities | 154 |
| 4.2.2 | The role of HIV-1 Tat in the development of Kaposi's sarcoma lesions | 154 |
| 4.2.3 | An infectious agent as a cause of Kaposi's sarcoma | 156 |
| 4.2.4 | The role of human herpesvirus 8 | 157 |
| | (a) Genomic organization and relationship to other primate herpesviruses | 157 |
| | (b) In-vivo tropism and association with Kaposi's sarcoma | 157 |
| 4.3 | Non-Hodgkin's lymphomas and other lymphoproliferative disorders | 158 |
| 4.3.1 | Pathological models of lymphomagenesis | 158 |
| | (a) HIV infection of lymphoid tissues and polyclonal B-cell hyperplasia | 160 |
| | (i) Pathological changes in HIV-infected lymphoid follicles | 161 |
| | (ii) Destruction of follicular centres and B-cell hyperplasia | 161 |
| | (iii) Chronic antigen stimulation | 162 |
| | (iv) Presence of HIV in tumour cells | 162 |
| | (b) Oligoclonal B-cell proliferation | 162 |
| | (i) Immunosuppression | 163 |
| | (ii) Cytokines | 163 |
| | (c) Genetic abnormalities | 165 |
| | (i) c-myc | 165 |
| | (ii) BCL-6 | 166 |
| | (iii) ras | 166 |
| | (iv) p53 | 166 |
| | (v) 6q Deletions | 168 |
| | (vi) Chromosome 1q abnormalities | 168 |
| 4.3.2 | Lymphotropic viruses | 168 |
| | (a) EBV | 168 |
| | (b) HHV-6 | 172 |
| | (c) HHV-8 | 173 |
| 4.3.3 | Conclusion | 173 |
| 4.4 | Cofactors in anal and cervical carcinomas and other cancers | 174 |

| | | |
|--|---|------------|
| 4.4.1 | The role of HPV in the molecular pathogenesis of anogenital cancers in immunocompetent patients..... | 175 |
| (a) | Status and level of HPV DNA in the natural history of infection | 175 |
| (b) | Expression of HPV proteins in the natural history of infection | 175 |
| (c) | Molecular mechanisms of transforming activity of HPV | 176 |
| (i) | Intrinsic properties of high-risk HPV E6 and E7 | 176 |
| (ii) | Regulation of E6 and E7 expression | 176 |
| 4.4.2 | Interactions between HIV and HPV | 177 |
| (a) | Effects of HIV-related immunosuppression on HPV replication and HPV-associated anogenital lesions | 178 |
| (b) | HIV Tat stimulation of cytokines and their role in genital lesions | 178 |
| (c) | Possible effect of HIV-1 Tat on HPV E6/E7 expression | 178 |
| 5. | Summary of data reported and evaluation..... | 179 |
| 5.1 | Exposure data | 179 |
| 5.2 | Human carcinogenicity data | 180 |
| 5.3 | Animal carcinogenicity data | 181 |
| 5.4 | Other relevant data and mechanistic considerations on HIV-1-associated neoplasms | 182 |
| 5.5 | Evaluation | 183 |
| 6. | References | 183 |
| Human T-cell lymphotropic viruses | | 261 |
| 1. | Exposure data | 261 |
| 1.1 | Structure, taxonomy and biology..... | 261 |
| 1.1.1 | Structure..... | 261 |
| 1.1.2 | Taxonomy and phylogeny | 261 |
| 1.1.3 | Host range..... | 263 |
| 1.1.4 | Related non-human primate viruses | 264 |
| 1.1.5 | Target tissue (<i>in vitro</i> and <i>in vivo</i>)..... | 266 |
| 1.1.6 | Genomic structure and properties of gene products | 266 |
| 1.1.7 | Other genes encoded by the open reading frames I, II and III in the HTLV-I pX region | 267 |
| 1.2 | Methods of detection | 268 |
| 1.2.1 | Serological detection of specific antibodies | 268 |
| 1.2.2 | Detection and characterization of viral nucleic acids | 269 |
| 1.2.3 | Isolation of HTLV-I and HTLV-II | 270 |
| 1.2.4 | Sero-indeterminate HTLV-I western blots | 270 |
| 1.2.5 | Seronegative HTLV-I-infected individuals | 271 |
| 1.3 | Epidemiology of HTLV infection | 271 |
| 1.3.1 | HTLV-I transmission..... | 271 |
| (a) | Mother-to-child transmission..... | 271 |

| | | |
|-------|--|-----|
| | (b) Sexual transmission | 272 |
| | (c) Transmission by blood | 273 |
| 1.3.2 | Animal models of HTLV-I transmission | 274 |
| 1.3.3 | Geographical distribution of HTLV-I | 274 |
| 1.3.4 | HTLV-I prevalence and demographic features of HTLV-I infection | 277 |
| 1.3.5 | Epidemiology of tropical spastic paraparesis/HTLV-I-associated myelopathy | 277 |
| 1.3.6 | Natural history of HTLV-I primary infection | 279 |
| 1.3.7 | Molecular epidemiology of HTLV-I | 279 |
| 1.3.8 | HTLV-II epidemiology | 280 |
| 1.4 | Clinical description of non-neoplastic disorders | 280 |
| 1.4.1 | HTLV-I infection | 280 |
| | (a) Tropical spastic paraparesis/HTLV-I associated myelopathy | 280 |
| | (b) Uveitis | 282 |
| | (c) Other inflammatory diseases | 283 |
| | (i) Infective dermatitis | 283 |
| | (ii) Polymyositis | 283 |
| | (iii) Alveolitis | 284 |
| | (iv) Arthritis (HTLV-I-associated arthropathy) | 284 |
| | (v) Thyroiditis | 285 |
| | (vi) Sjögren's syndrome | 285 |
| | (d) Immune suppression | 285 |
| 1.4.2 | HTLV-II infection | 285 |
| 1.4.3 | HTLV/HIV co-infection | 286 |
| 1.5 | Control and prevention | 286 |
| 2. | Studies of cancer in humans | 287 |
| 2.1 | T-cell malignancies | 287 |
| 2.1.1 | HTLV-I infection and adult T-cell leukaemia/lymphoma | 287 |
| | (a) Clinical description | 287 |
| | (i) Distribution by subtype | 287 |
| | (ii) Laboratory findings | 289 |
| | (iii) Histological characteristics | 290 |
| | (iv) Genetic studies | 291 |
| | (v) Prognosis | 292 |
| | (vi) Prevention of ATLL | 292 |
| | (b) Epidemiology | 292 |
| | (i) Geographical distribution | 293 |
| | (ii) Age- and sex-distribution of ATLL | 294 |
| | (iii) Cohort studies | 297 |
| | (iv) Case-control studies on co-factors | 297 |
| 2.1.2 | HTLV-I infection and cutaneous T-cell lymphomas | 300 |
| 2.1.3 | HTLV-II infection | 301 |

| | | |
|-------|---|-----|
| 2.2 | Other malignancies | 302 |
| 2.2.1 | HTLV-I..... | 302 |
| | (a) Case reports and case series | 302 |
| | (b) Cohort studies | 303 |
| | (c) Case-control studies | 303 |
| 2.2.2 | HTLV-II..... | 306 |
| 3. | Studies of cancer in animals | 306 |
| 3.1 | HTLV-I in animal models | 306 |
| 3.1.1 | Non-human primates | 306 |
| 3.1.2 | Other models..... | 308 |
| 3.2 | STLV-I in non-human primates | 308 |
| 3.2.1 | STLV-I-associated lymphomas | 308 |
| 3.2.2 | Pathological and molecular aspects | 310 |
| 3.3 | Bovine leukaemia virus in sheep and cattle..... | 311 |
| 3.3.1 | Disorders induced by BLV | 313 |
| | (a) Cattle | 314 |
| | (b) Sheep..... | 314 |
| 3.3.2 | Pathological and molecular aspects | 314 |
| | (a) Cattle | 314 |
| | (b) Sheep..... | 315 |
| | (c) Mechanistic studies..... | 316 |
| 3.3.3 | Vaccination trials..... | 316 |
| 4. | Other data relevant to an evaluation of carcinogenesis and its mechanisms..... | 316 |
| 4.1 | General observations on retroviral oncogenesis | 316 |
| 4.2 | Host factors..... | 317 |
| 4.2.1 | The role of the HLA system in HTLV-I infection..... | 317 |
| 4.2.2 | Immune surveillance and escape | 318 |
| | (a) Antibodies | 318 |
| | (b) T-cells | 318 |
| 4.2.3 | Host genetic factors required during the transition to ATLL | 318 |
| 4.3 | Viral factors | 320 |
| 4.3.1 | Proviral load and clonal integration of HTLV-I infection..... | 320 |
| 4.3.2 | The role of Tax in cellular transformation/immortalization | 321 |
| | (a) Transforming/immortalizing properties of HTLV-I Tax <i>in vitro</i> | 321 |
| | (i) Immortalizing effects on T-cells <i>in vitro</i> | 321 |
| | (ii) Transforming effect of Tax on fibroblasts cultures <i>in vitro</i> | 321 |
| | (b) Tumorigenic properties of <i>tax</i> in transgenic mice | 321 |
| 4.3.3 | Pathways of Tax-mediated transactivation of cellular genes | 324 |
| 4.3.4 | Differences between HTLV-I-transformed T-cells and ATLL cells..... | 327 |
| 4.3.5 | The role of other viral and host cell proteins in lymphocyte stimulation and leukaemogenesis | 328 |

| | |
|---|-----|
| 4.3.6 Differences between HTLV-I and HTLV-II..... | 330 |
| 5. Summary of data reported and evaluation..... | 330 |
| 5.1 Exposure data | 330 |
| 5.2 Human carcinogenicity data | 331 |
| 5.3 Animal carcinogenicity data..... | 332 |
| 5.4 Molecular mechanisms of leukaemogenesis | 332 |
| 5.5 Evaluation..... | 333 |
| 6. References | 334 |
| ABBREVIATIONS..... | 391 |
| SUPPLEMENTARY CORRIGENDA TO VOLUMES 1-66..... | 395 |
| CUMULATIVE INDEX TO THE <i>MONOGRAPHS</i> SERIES..... | 397 |

NOTE TO THE READER

The term 'carcinogenic risk' in the *IARC Monographs* series is taken to mean the probability that exposure to an agent will lead to cancer in humans.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a monograph does not mean that it is not carcinogenic.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Unit of Carcinogen Identification and Evaluation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Unit of Carcinogen Identification and Evaluation, so that corrections can be reported in future volumes.